Hep C Protease Inhibitors May Not Be Cost-Effective For Some First-Time Treatment Takers
November 27

Blood Thinner Reduces Liver Vein Blood Clots, Protects Liver Functioning in People With Cirrhosis
November 17

Milk Thistle Extract Comparable to Placebo in Hep C Liver Enzyme Study
November 15

TRANSGENE : and Jennerex Announce Final Data at AASLD From JX594/TG6006 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients with Advanced Liver Cancer
November 14

Study Explores Economic Cost of Hepatitis C Patients with Advanced Liver Disease
November 10

Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD
November 9

Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
November 9

12-Week On-Treatment Results from Large Phase IIb Study (COMMAND-1) of Bristol-Myers Squibb's NS5A Inhibitor Daclatasvir Support Anti-HCV Activity and Safety Profile Observed in Earlier Studies
November 9

Cytheris Announces Interim Results from ECLIPSE 2 Hepatitis C Multicenter Study of IL-7 in Chronically Infected Genotype 1 and 4 Nonresponders to Standard of Care (SOC)
November 8

SCYNEXIS Presents Data Demonstrating that SCY-635 Restores the Body's Innate Immune Response to HCV and Could be an Effective Replacement for Recombinant Interferon
November 8

Records Show Deaths Associated With Hepatitis C Have Overtaken Deaths Caused by HIV
November 8

Glaxo Says Promacta for Hepatitis C Cured Patients in Trial
November 8

Transgene's Therapeutic HCV Vaccine TG4040 Combined with Commonly Used Treatment Achieves Substantial Viral Suppression in Randomized Phase II trial
November 8

Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients
November 8

Twelve Weeks Interferon-Free PSI-7977 Regimen Cures 100 Percent Hep C Genotype 2/3
November 5

Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
November 5

Presidio Pharmaceuticals advances with its HCV antiviral drug discovery, development programs
November 5

Interim Data for Merck's VICTRELIS™ (boceprevir) in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1 to be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting
November 5

Santaris Pharma A/S Phase 2a data of miravirsen shows dose-dependent, prolonged viral reduction of 2-3 logs HCV RNA after four-week treatment in Hepatitis C patients
November 5

Novartis DEB025 data showed viral clearance as early as six weeks and potential for interferon-free therapy in hepatitis C patients
November 5

Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK™ (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR)
November 5